Drug intelligence / Profile preview

CLDE-361

Development stage: Preclinical
Lead developer: Century Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

CLDE-361 is a preclinical, allogeneic cell therapy product candidate developed initially by Clade Therapeutics and now part of Century Therapeutics' pipeline. It is an αβ induced T (iT) cell therapy engineered to target B-cell maturation antigen (BCMA), a protein expressed on B cells. The primary indication under development for CLDE-361 is myasthenia gravis, an autoimmune disease. The therapy leverages iPSC-derived αβ T cells designed for off-the-shelf use, aiming to modulate or deplete BCMA-expressing cells implicated in the pathogenesis of autoimmune disorders[1][3][5][6][8].

Targets

BCMA (B-cell maturation antigen)

Beyond the preview

Go deeper on CLDE-361.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CLDE-361.

Explore the full profile